Vaccine for 'Older Individuals'

McGill Refresher Course 2020



https://www.youtube.com/watch?v=fQ8hGMt7IZk

Brian J Ward

McGill Division of Infectious Diseases Research Institute - McGill University Health Center

LEARNING OBJECTIVES

After attending this session, participants will be able to: 1) Make better use of the vaccines routinely used to protect older adults

2) Explain the strengths and weaknesses of routine vaccines to their older patients

3) Answer the most common questions about vaccines routinely used in older people



Conflict of Interest Statement (Last 5 Years)

Position in Pharma	Medical Officer for Medicago Inc. (Oct 2011 - present)				
Consulting	Pfizer, Merck, Novartis, GSK, Sanofi Pasteur MSSS, US Dept of Justice (Vaccine Compensation Programs)				
Contracts	Vaccine trials for virtually all companies				
Shared Awards	Shared CIHR Team grant (Laval U, GSK) CIHR-Industry grant (Medicago) Shared CQDM grant (Medicago, Laval U, SNC Lavalin)				
Occasional Speakers Honoraria	Pfizer, Sanofi Pasteur,Novartis				
Investments	None				

One Tried & True Approach to Staying Alive

19 years

25 years



tps://www.pinterest.ca/pin/322429654562572305/




https://www.datingadvice.com/for-men/the-curse-of-the-older-manand-the-younger-woman

Another ...



We're here to talk about VACCINES

www.urbandojo.com



Box 3

Doherty M et al Vaccination of special populations: Protecting the vulnerable. Vaccine. 2016 Dec 20;34(52):6681-6690.

Vaccine Coverage in Older Individuals is Sub-Optimal

USA (\geq 65years of age)

- 67% for influenza vaccine
- 55-60% for tetanus and pneumococcal vaccines
- 24% for herpes zoster vaccine

Canada

- ~60% for influenza vaccine (varies by year!)
- 38% for tetanus (2004) and 40% for pneumococcus (2018)
- $\sim 8\%$ for herpes zoster vaccine (2014)

Doherty M et al Vaccination of special populations: Protecting the vulnerable. Vaccine. 2016 Dec 20;34(52):6681-6690. Trends in influenza **vaccine coverage** and **vaccine** hesitancy in **Canada**, 2006/07 to 2013/14: results from crosssectional survey data. Buchan SA, Kwong JC. CMAJ Open. 2016 Aug 19;4(3):E455-E462. Herpes zoster **vaccine** (HZV): utilization and **coverage** 2009 - 2013, Alberta, **Canada**. Liu XC, Simmonds KA, Russell ML, Svenson LW. BMC Public Health. 2014 Oct 23;14:1098. **Coverage** of anti-**tetanus vaccinations** in adults in **Canada**-year 2002.]. Coulibaly N, De Serres G. Can J Public Health. 2004 Nov-Dec;95(6):456-9.

Adult Vaccines Save Money



HHS Public Access

Vaccine. Author manuscript; available in PMC 2020 January 07.

Published in final edited form as: Vaccine. 2019 January 07; 37(2): 226–234. doi:10.1016/j.vaccine.2018.11.056.

Cost-effectiveness of adult vaccinations: A systematic review

Andrew J. Leidner^{a,*}, Neil Murthy^{b,c}, Harrell W. Chesson^d, Matthew Biggerstaff^b, Charles Stoecker^e, Aaron M. Harris^d, Anna Acosta^b, Kathleen Dooling^b, and Carolyn B. Bridges^a ^aBerry Technology Solutions, USA

^bNational Center for Immunization and Respiratory Diseases, CDC, USA

°Epidemic Intelligence Service, CDC, USA

^dNational Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC, USA

eSchool of Public Health and Tropical Medicine, Tulane University, USA

- 1688 publications: 78 publications retained
- Cost savings by disease 56% for influenza 31% for pneumococcal 23% for tetanus-diphtheria-pertussis •
 - Cost per QALY of ≤\$100,000 100% for influenza 100% for pneumococcal 71% for herpes zoster 50% for tetanus-diphtheria-pertussis

Cost-effectiveness of adult vaccinations: A systematic review.

Leidner AJ, Murthy N, Chesson HW, Biggerstaff M, Stoecker C, Harris AM, Acosta A, Dooling K, Bridges Cbet al


DANGER !!!

https://www.dreamstime.com/photos-images/old-man-gardening-rose-bush.html

Tetanus Clostridium tetani



immunizebc.ca




chemgapedia.de

- Tetanospasmin
- Second most potent toxin (after Botulinum D toxin)
- LD50 in 1ng/Kg range

Amount needed to kill is less than amount needed for immune response

Pertussis and Chronic Cough

164 adults with chronic cough and 164 matched controls



- 4 culture-positive B. pertussis
- 11 PCR-positive
- 33 with evidence of recent infection

Bordetella **pertussis** and **chronic cough** in adults. Birkebaek NH, Kristiansen M, Seefeldt T, Degn J, Moller A, Heron I, Andersen PL, Moller JK, Ostergård L. Clin Infect Dis. 1999 Nov;29(5):1239-42.



Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine

The health and economic burden of pertussis in Canada: A microsimulation study



Vaccine

Ashleigh McGirr^a, David N. Fisman^{a,b,*}, Ashleigh R. Tuite^a

^a Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

^b Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Canada

	Ontario		Canada	
Age Group	2012	2013	2012	2013
<6 mo	799	293	2528	951
6 mo to 4 y	997	282	3693	1013
5 to 17 y	2342	529	12,504	2967
18 to 64 y	1605	372	5782	1909
65+ y	113	45	1025	332
Total	5855	1520	25,532	7173

. McGirr A et al. The health and economic burden of pertussis in Canada: A microsimulation studyVaccine. 2019 Nov 20;37(49):7240-7247.


Pertussis in high-risk groups: an overview of the past quarter-century

Victoria A Jenkins 向 , Miloje Savic 🍺 , and Walid Kandeil 🍺

Vaccines, GSK, Wavre, Belgium

- USA data between 2011 and 2015 \rightarrow 15,942 cases (20.3 per 100,000)
- 3.2% required hospitalization
 - 29.6% of cases and 4.5% of hospitalizations in 12–20-year-olds
 - 18% of cases and 14.8% of hospitalizations in 21-64-year-olds





Jenkins VA, et al. Pertussis in high-risk groups: an overview of the past quarter-century. Hum Vaccin Immunother. 2020 Apr 16:1-9.

Influenza



nughbriss.com

nost NO cases of influenza (so far) in 2020





https://byrslf.co/silent-thoughts-about-the-silence-in-relationships-426d733dba3f

Influenza: OutcomesCatastrophic disabilityLoss of independence in ≥ 3 ADL72% who experience catastrophicdisability have been hospitalizedLeading causes of catastrophic disability

Strokes

CHF

Pneumonia and influenza


Ischemic heart disease

Cancer

Hip fracture

Ferrucci et al. JAMA 277:728, 1997 Barker et al. Arch Int Med 158:645, 1998 Falsey et al. *N Engl J Med*. 2005;352:1749 McElhaney JE, et al Vaccine. 2012 Mar 9;30(12):2060-7.

Influenza: Predictor of Excess Mortality



Meta-Analyzed to Death





Figure 2: Vaccine efficacy compared with placebo (Mantel-Haenszel random-effects model)

(A) Trivalent inactivated influenza vaccine in adults aged 18–64 years. (B) Live attenuated influenza vaccine in children aged 6 months to 7 years. Studies were prospective (risk ratio) which are equivalent to case-control (odds ratio). n=cases of influenza. N=group size.

"Even at 38% Efficacy ..."



Effects of Influenza Vaccination in the United States During the 2017-2018 Influenza Season.

Rolfes MA, Flannery B, Chung JR, O'Halloran A, Garg S, Belongia EA, Gaglani M, Zimmerman RK, Jackson ML, Monto AS, Alden NB, Anderson E, Bennett NM, Billing L, Eckel S, Kirley PD, Lynfield R, Monroe ML, Spencer M, Spina N, Talbot HK, Thomas A, Torres SM, Yousey-Hindes K, Singleton JA, Patel M, Reed C, Fry AM; US Influenza Vaccine Effectiveness (Flu VE) Network, the Influenza Hospitalization Surveillance Network, and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention. Clin Infect Dis. 2019 Nov 13;69(11):1845-1853.




Recombinant Influenza Vaccines

• Insect Cell-derived vaccine (HA)

- FluBlok™
- 45µg of each strain with no adjuvant
- more effective in subjects >50 years old
- bought by Sanofi not sure what they will do with it yet
- being tried with an adjuvant
- not available in Canada (yet)

• Plant-derived recombinant (HA)

- FluforzaTM
- 15µg of each strain in a virus-like particle
- produced in Nicotiana benthamiana plants
- Currently before regulators in Canada, USA and elsewhere
- being tried with an adjuvant (AS03) in the elderly
- Insect Cell recombinant (HA)
 - No name yet
 - uses proprietary adjuvant Matrix M



Ward BJ et al. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (265 years): two multicentre, randomised phase 3 trials . Lancet. 2020 Nov 7;396(10261):1491-1503




medicago






Expanding Technologies for Seasonal Influenza Vaccines



Harding AT, Heaton NS. Efforts to Improve the Seasonal Influenza Vaccine. Vaccines (Basel). 2018 Mar 30;6(2). pii: E19. doi: 10.3390/vaccines6020019.


Influenza Vaccines for the Elderly

 High-Dose Inactivated (Fluzone) Tri-Valent Quadrivalent




```
MIT Mathematics
```

2) Re Real World Data for the Elderly Little-to-No benefit from quadrivalent Benefit to cell-based & recombinant in mismatch years Small (5-10%) benefit from adjuvant Modest (10-15%) benefit from HD/Recombinant Advantages generally greatest for serious outcomes
4) Atty mactivated quadrivation Cell-based (Flucelvax) better than egg-based Not available in Canada yet




Influenza & S. pneumoniae Synergistic Effect on Mortality (Animals)



Mortality was 100% in mice challenged with S. pneumoniae after influenza

Adapted from McCullers JA, Rehg JE. J Infect Dis. 2002;186:341-350. Slide courtesy of Dr. Keith Klugman.

Streptococcus pneumoniae





radiopaedia.org

- World-wide distribution
- Encapsulated bacterium (polysaccharide)
- More than 90 different serotypes
- Predominant serotypes vary by region
- Antibodies (opsinization & phagocytosis) essential
- Babies make very poor responses to polysaccharides
- Mortality highest in infants and elderly

Streptococcus pneumoniae

rockefeller.edu

Pneumococcal Conjugate Vaccines

Wyeth	Pfizer	GSK	South African	Who's Next	PPV
(Licensed)	(13-Valent)	(10-Valent)	(9-Valent)	(15 Valent)	(23 Valent)
4	1	1	1	1	1 17f
6b 9v 14 19f 18c 23f	3 4 5 6a 6b 7f 9v 14 19a 19f 18c 23f	4 5 6b 7f 9v 14 19f 18c 23f	4 5 6b 9v 14 19f 18c 23f	3 4 5 6a 6b 7f 9v 14 18c 19a 19f 22f 23f 33f	1 17f 2 18c 3 19a 4 19f 5 20 6b 22f 7f 23f 8 33f 9n 9v 10a 11a 12f 14 15b 100



<u>Hum Vaccin Immunother</u>. 2019; 15(3): 530–539. Published online 2019 Jan 16. doi: <u>10.1080/21645515.2018.1532249</u> PMCID: PMC6605726 PMID: <u>30648919</u>

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

<u>Helen L. Stacey</u>,^a Jeffrey Rosen,^b James T. Peterson,^c Angela Williams-Diaz,^d Vanita Gakhar,^d <u>Tina M. Sterling</u>,^d Camilo J. Acosta,^d Katrina M. Nolan,^d Jianing Li,^d Alison Pedley,^d <u>Patrice Benner</u>,^d Chitrananda Abeygunawardana,^d Michael Kosinski,^d William J. Smith,^d <u>Hari Pujar</u>,^d and <u>Luwy K. Musey</u>^d

► Author information ► Article notes ► Copyright and License information Disclaimer

Panel A: PCV15-A versus PCV13

		PCV	15	PCV13	Fold-Diff. (95% Cl
PCV13 Types		n G	GMT n	GMT	
1	H-+	227 20	5.27 22	120.62	1.70 (1.13, 2.56)
3	H+++	226 10	4.13 219	32.86	3.17 (2.28, 4.41)
4	H	224 13	25.04 220	1189.65	1.11 (0.80, 1.56)
5		227 27	3.77 22	264.46	1.04 (0.69, 1.55)
6A		226 38	74.37 222	4681.75	0.83 (0.58, 1.18)
6B	H	223 45	65.07 219	3847.94	1.19 (0.85, 1.65)
7F	H	227 26	38.66 219	3642.19	0.72 (0.56, 0.94)
9V	H	227 25	48.29 223	2116.03	1.20 (0.88, 1.64)
14	H+++	227 35	06.39 222	2 3094.07	1.13 (0.86, 1.50)
18C	+	227 19	12.44 219	1524.78	1.25 (0.92, 1.70)
19A	H	227 19	49.84 220	2027.29	0.96 (0.74, 1.25)
19F		227 81	5.77 222	2 795.23	1.03 (0.75, 1.41)
23F		224 12	36.73 22	1617.87	0.76 (0.53, 1.10)
0.33 (0.5 1 2 3				
Fold-d	lifference Log 10 Scale PCV15/PCV13				


Panel B: PCV15-B versus PCV13

		PCV15	PCV13	Fold-Diff. (95% Cl)
PCV13 Ty	pes	n GMT	n GMT	
1	⊢ •−1	228 139.93	221 120.62	1.16 (0.77, 1.75)
3		228 61.04	219 32.86	1.86 (1.33, 2.59)
4	⊢ •−1	223 922.20	220 1189.65	0.78 (0.55, 1.09)
5	H-4-1	226 265.10	221 264.46	1.00 (0.67, 1.51)
6A		227 4869.20	222 4681.75	1.04 (0.73, 1.48)
68		224 5092.52	219 3847.94	1.32 (0.95, 1.84)
7F	H+++	226 2877.49	219 3642.19	0.79 (0.61, 1.02)
9V		225 1929.49	222 2116.03	0.91 (0.67, 1.24)
14	1	224 2657.99	222 3094.07	0.86 (0.65, 1.14)
18C	⊢ ⊷⊣	227 2662.97	219 1524.78	1.75 (1.29, 2.37)
19A	+++	226 2434.86	220 2027.29	1.20 (0.93, 1.56)
19F		227 1046.24	222 795.23	1.32 (0.96, 1.81)
23F	H+++	228 2081.62	221 1617.87	1.29 (0.89, 1.86)
	0.33 0.5 1 2 3 old-difference Log 10 Scale			

PCV15/PCV13

Conjugate (7): Indirect Effect—IPD (U.S.)

Rate of Vaccine-type (VT) IPD Before and After Introduction of PREVNAR, by Age Group and Year[†]



[‡]*p*<0.05, 2003 vs 1998-1999

PREVNAR vaccination was associated with a reduction in IPD in vaccinated and unvaccinated populations

Adapted from CDC. Morb Mortal Wkly Rep. 2005;54:893-897.

'Best' Strategy for Adults

Identify high risk (\geq 65yo, co-morbidities) Start with conjugate vaccine

- Highest valency available
- Prevnar 13TM for the moment

8-12 months later – polysaccharide vaccine

- Pneumo23TM for the moment
- minimum of 8 weeks if urgent

Boosters?


- Not yet known for conjugate vaccines
- Up to every 5-10 years for Pneumo23

VZV & Shingles



hardinmd.lib.uiowa.edu

Hospitalizations & Consultations for Herpes Zoster in Canadian Provinces



Herpes Zoster Burden in Canadian Provinces: A Narrative Review and Comparison with Quebec Provincial Data. Letellier MC, Amini R, Gilca V, Trudeau G, Sauvageau C. Can J Infect Dis Med Microbiol. 2018 Oct 21;2018:3285327.

ShingrixTM is a Good Vaccine

- Vaccine that targets VZV glycoprotein E (gE) and ASO1_B adjuvant
- Adjuvant MPL + QS21 (oil-in-water + TLR4 agonist)
- Need 2 doses 2-6 months apart (need for boosters not known but likely)
- Works in very old and the immunocomprimised (lower efficacy predicted but at least you can use it)
- Recommended for >50 yo and can give to those who have had Zostavax[™]

When are we going to have to give a booster?





What's Next for the Elderly?



RSV vaccine Better influenza vaccines Cancer vaccines C. difficile vaccine

We (me included) are Going to Stay Healthy and Active Longer



Appropriate use of vaccines will have an ever larger role to play

Hopefully you won't feel like this after my talk ...